9.1 Manufacturers (Rx & OTC) & Virtual Manufacturers
Key Takeaways
A drug manufacturer is the entity that holds FDA approval for a product and produces it; Rx drugs reach market via NDA, ANDA, or BLA, while OTC drugs reach market via an FDA monograph or an NDA
All drug manufacturers must register with FDA and list each drug they make (NDC registration); FDA-registered facilities are subject to cGMP inspection
Under DSCSA, manufacturers must serialize packages with a product identifier and pass transaction information and a transaction statement to the next trading partner (transaction history ended November 27, 2023)
Manufacturers normally sell to wholesale distributors; direct-to-pharmacy or direct-to-hospital sales exist but are less common and still trigger DSCSA obligations
A virtual manufacturer owns the product and the FDA approval but contracts out physical production to a contract manufacturer and logistics to a 3PL — it is still a DSCSA trading partner and must register with FDA
The manufacturer sits at the very top of the pharmaceutical supply chain. It is the entity that holds the FDA approval for a drug and produces (or arranges production of) that drug. Everything downstream — wholesalers, repackagers, 3PLs, pharmacies — traces product back to a manufacturer. For the PTCB Supply Chain exam, you must know how Rx and OTC manufacturers reach market, what FDA registration they carry, and what DSCSA places on them.
How Drugs Reach Market: Rx vs OTC
Prescription (Rx) and over-the-counter (OTC) drugs take different regulatory pathways to market, and that difference shapes what the manufacturer must do.
Prescription Drugs — NDA, ANDA, and BLA
A new Rx drug reaches market through one of three FDA approval pathways:
- New Drug Application (NDA) — used for a new molecular entity or a major change to an existing product. The NDA is the most demanding pathway, requiring full clinical evidence of safety and efficacy. The manufacturer that holds an approved NDA is the reference listed drug (RLD) holder.
- Abbreviated New Drug Application (ANDA) — used for a generic drug. The ANDA applicant must demonstrate bioequivalence to the RLD but does not repeat the clinical trials. An ANDA holder is a manufacturer of a generic drug.
- Biologics License Application (BLA) — used for biological products (e.g., monoclonal antibodies, vaccines, biosimilars). A biosimilar is approved under a BLA, not an NDA.
OTC Drugs — Monograph or NDA
An OTC drug generally reaches market in one of two ways:
- OTC Monograph — FDA publishes a final monograph specifying the active ingredient, dose, indications, and labeling. A manufacturer that follows the monograph can market the OTC drug without a separate NDA. The monograph essentially pre-approves the product class.
- NDA — some OTC drugs (e.g., those first approved as Rx and then switched to OTC) are marketed under an NDA rather than under a monograph.
The exam often tests the monograph pathway as the OTC-specific route distinct from the Rx NDA/ANDA/BLA routes.
FDA Registration and Drug Listing
Every facility that manufactures a drug for the U.S. market must register with FDA and submit a National Drug Code (NDC) listing for each drug. Registration is the mechanism that places the facility under FDA inspection for current Good Manufacturing Practice (cGMP). cGMP covers everything from facility design and sanitation to batch records, stability testing, and quality release — a batch that fails cGMP release cannot legally enter commerce.
Key points the exam rewards:
- FDA registration is required of manufacturers — it is not optional.
- NDC listing assigns the 10- or 11-digit NDC that downstream trading partners use to identify the product.
- cGMP compliance is enforced through FDA inspection; a Form 483 may be issued for observed violations.
DSCSA Obligations on Manufacturers
Under the Drug Supply Chain Security Act (DSCSA), a manufacturer of a covered prescription product is an authorized trading partner and carries specific obligations:
- Serialization — the manufacturer must affix a product identifier (National Drug Code, serial number, lot number, and expiration date) in both human-readable and machine-readable (2D Data Matrix) form to each package. Serialization is the foundation of package-level traceability.
- Transaction data — when the manufacturer sells or transfers ownership of a covered product to the next trading partner, it must pass Transaction Information (TI) and Transaction Statement (TS). TI contains the product identifier, lot, expiration date, transaction date, and quantity; TS is the attestation by the seller. A third document, Transaction History (TH) — the cumulative chain of ownership back to the manufacturer — was historically part of this set but has not been required since section 582(k)(1)'s November 27, 2023 sunset.
- Suspect and illegitimate product — the manufacturer must investigate and notify FDA and immediate trading partners if it determines product is suspect or illegitimate, and must quarantine and not distribute illegitimate product.
- Verification — the manufacturer must respond to verification requests (e.g., a downstream dispenser asking "is this package legitimate?") within a specified timeframe.
Note that OTC monograph drugs are generally outside DSCSA. The serialization and T3 obligations attach to covered prescription products, which is why a technician must not assume every drug in the building carries T3 paper.
Manufacturer Sales Channels
The normal flow is manufacturer → wholesale distributor → pharmacy/hospital. Manufacturers sell the large majority of volume to wholesalers, who aggregate and distribute. Two narrower channels also exist:
- Direct-to-pharmacy / direct-to-hospital — some manufacturers (especially of specialty, limited-distribution, or cold-chain biologics) ship directly to a pharmacy or health system, bypassing the wholesaler. This is common for limited-distribution drugs (LDDs) and some specialty products.
- Authorized distribution network — a manufacturer may designate certain wholesalers as authorized distributors of its products. Product sold through the authorized network is presumptively genuine; product appearing outside that network raises a diversion flag.
Regardless of channel, DSCSA obligations follow the product: a manufacturer that sells direct to a hospital must still pass T3 data to that hospital.
Virtual Manufacturers
A virtual manufacturer is an entity that owns the product and the FDA approval (the NDA, ANDA, or BLA is held in its name) but outsources the physical work: a contract manufacturer makes the drug, and a Third-Party Logistics provider (3PL) warehouses and ships it. The virtual manufacturer does not operate its own production line or its own warehouse.
Why this matters for the exam:
- A virtual manufacturer is still a manufacturer for regulatory purposes — it must register with FDA, it is an authorized trading partner under DSCSA, and it must serialize and pass T3.
- The fact that physical handling is contracted out does not move the virtual manufacturer into the "wholesaler" or "3PL" box. Ownership of the approval — not ownership of the building — defines the role.
- A common exam trap is to treat a virtual manufacturer as something less than a manufacturer because it has no factory. The correct view is the opposite: it carries the same manufacturer obligations, layered on top of contract oversight of its contract manufacturer and 3PL.
Summary Table — Manufacturer Types
| Type | Approval Path | FDA Registered | DSCSA Serialization/T3? | Notes |
|---|---|---|---|---|
| Brand Rx manufacturer | NDA | Yes | Yes (covered Rx) | Holds the RLD |
| Generic manufacturer | ANDA | Yes | Yes (covered Rx) | Must show bioequivalence |
| Biologic/biosimilar manufacturer | BLA | Yes | Yes (covered Rx) | Vaccines, mAbs, biosimilars |
| OTC monograph manufacturer | OTC monograph | Yes | Generally no (outside DSCSA) | Follows the monograph |
| Virtual manufacturer | Holds NDA/ANDA/BLA | Yes | Yes (covered Rx) | Outsources production to a contract manufacturer |
The unifying rule: registration and DSCSA obligations attach to the entity that holds the approval and puts the product into commerce, whether or not it runs the factory. The pathway (NDA/ANDA/BLA/monograph) determines the approval burden; DSCSA determines the downstream traceability burden.
A new generic version of an existing brand-name prescription drug reaches the U.S. market through which FDA approval pathway?
Abbreviated New Drug Application (ANDA)
Over-the-counter monograph
Biologics License Application (BLA)
New Drug Application (NDA)
Which statement correctly describes a virtual manufacturer under DSCSA?
It is exempt from FDA registration because it does not physically produce the drug
It owns the FDA approval and must serialize and pass T3, even though a contract manufacturer makes the drug and a 3PL handles logistics
It is classified as a wholesale distributor because it does not own a factory
It may sell only OTC products because it has no manufacturing facility
Under DSCSA, which identifier must a manufacturer affix to each package of a covered prescription product in both human-readable and machine-readable form?
A 12-digit UPC barcode
Only the lot number and expiration date
A product identifier containing the National Drug Code, serial number, lot number, and expiration date (2D Data Matrix)
The FDA Establishment Registration number alone
An OTC monograph drug that a manufacturer markets without a separate NDA is generally treated how under DSCSA?
It must carry a BLA before it can be sold over the counter
It requires the same package-level serialization as a brand Rx drug
It is prohibited from being distributed by wholesale distributors
It is largely outside DSCSA, so manufacturer serialization and T3 obligations generally do not attach to it
Sections you finish are checked off in the contents.